A New Approach to Treating Chronic Wounds
Millions of people suffer from chronic non-healing wounds, causing pain, mobility loss, and a reduced quality of life. Traditional treatments often fail, leaving patients at risk of severe complications, including amputation. Aurealis Therapeutics has developed AUP-16, a first-in-class, genetically engineered 4-in-1 biological drug designed to activate and accelerate the wound healing process.
How AUP-16 Works
Chronic wounds, such as diabetic foot ulcers (DFUs), often remain trapped in a prolonged inflammatory state, preventing natural healing. AUP-16 is a genetically engineered lactic acid bacterium that produces three human therapeutic proteins and acts as a fourth therapeutic component itself. Together, they target all stages of wound healing:
- Resetting Inflammation: AUP-16 triggers the immune system, converting chronic inflammation into a healthy acute response.
- Creating a Healing Environment: The drug shifts the wound’s state from hostile inflammation to a regenerative, pro-healing condition.
- Tissue Regeneration: AUP-16 promotes fibroblast proliferation, extracellular matrix formation, and new blood vessel growth.
- Final Wound Closure: The skin layers are rebuilt, reinforcing and fully restoring tissue integrity.
Backed by preclinical studies and ongoing clinical trials, AUP-16 has demonstrated superior safety and efficacy for diabetic foot ulcers and other chronic wounds.
➡ Learn more at aurealistherapeutics.com
